GLPG0634
| Code | Size | Price |
|---|
| SYN-1158-M100 | 100 mg | Enquire |
Quantity:
| SYN-1158-M050 | 50 mg | Enquire |
Quantity:
| SYN-1158-M001 | 1 mg | £233.00 |
Quantity:
| SYN-1158-M005 | 5 mg | £385.00 |
Quantity:
| SYN-1158-M010 | 10 mg | £549.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
GLPG-0634; Filgotinib
Appearance:
Solid.
CAS:
1206161-97-8
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
InChiKey:
RIJLVEAXPNLDTC-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1206161-97-8. Formula: C21H23N5O3S. MW: 425.5. GLPG0634 is a novel and specific inhibitor of JAK1 and JAK2 with IC(50) of 10nM and 28nM respectively measured by in vitro kinase assays (ATP 2µM). In particular GLPG0634, while being a potent inhibitor of JAK1 and JAK2 does not inhibit TYK2 or JAK3, and GLPG0634 exhibits a dramatically improved in vivo potency over structurally similar compounds. May be used for the prevention of variety of conditions in animals including inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation and/or diseases associated with hypersecretion of IL-6.
Molecular Formula:
C21H23N5O3S
Molecular Weight:
425.5
Package Type:
Plastic Vial
Product Description:
GLPG0634 is a novel and specific inhibitor of JAK1 and JAK2 with IC(50) of 10nM and 28nM respectively measured by in vitro kinase assays (ATP 2µM). In particular GLPG0634, while being a potent inhibitor of JAK1 and JAK2 does not inhibit TYK2 or JAK3, and GLPG0634 exhibits a dramatically improved in vivo potency over structurally similar compounds. May be used for the prevention of variety of conditions in animals including inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation and/or diseases associated with hypersecretion of IL-6.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases: L. Van Rompaey, et al.; J. Immunol. 191, 3568 (2013)
Related Products
| Product Name | Product Code | Supplier | LY2784544 | SYN-1196 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|